Literature DB >> 26446314

NASH, from diagnosis to treatment: Where do we stand?

Stephen A Harrison1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26446314     DOI： 10.1002/hep.28275

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  5 in total

1.  A Model to Predict Significant Macrosteatosis in Hepatic Grafts.

Authors:  Ahmed Swelam; René Adam; Lelde Lauka; Luiza Basilio Rodrigues; Sherif Elgarf; Mylène Sebagh; Nicolas Golse; Antonio Sa Cunha; Daniel Cherqui; Denis Castaing; Marc-Antoine Allard
Journal:  World J Surg       Date:  2020-04       Impact factor: 3.352

2.  Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: A prospective cohort study.

Authors:  Elliot B Tapper; Michelle Lai
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

3.  Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management.

Authors:  Preya Janubhai Patel; Kelly Lee Hayward; Rathiga Rudra; Leigh Ula Horsfall; Fabrina Hossain; Suzanne Williams; Tracey Johnson; Nigel Neil Brown; Nivene Saad; Andrew Donald Clouston; Katherine Anne Stuart; Patricia Casarolli Valery; Katharine Margaret Irvine; Anthony William Russell; Elizabeth Ellen Powell
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

Review 4.  Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.

Authors:  Paola Portillo-Sanchez; Kenneth Cusi
Journal:  Clin Diabetes Endocrinol       Date:  2016-04-12

5.  Serum interleukin-38 levels correlated with insulin resistance, liver injury and lipids in non-alcoholic fatty liver disease.

Authors:  Jun Cao; Lin Hua; Shipei Zhang; Jinping Tang; Fan Ke; Zhouhuan Wu; Guohui Xue
Journal:  Lipids Health Dis       Date:  2022-08-10       Impact factor: 4.315
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.